Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Bron, France.
Rev Neurol (Paris). 2024 Nov;180(9):957-962. doi: 10.1016/j.neurol.2024.08.004. Epub 2024 Sep 14.
In this mini-review, we focus on novelties in the field of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD). We first describe the proposed criteria for MOGAD and evaluate their impact and potential limitations, with a highlight on the subgroups of patients tested MOG-antibody positive only in the cerebrospinal fluid. We then propose a brief state of the art on the current knowledge on the so-call "double seronegative" NMOSD group, regarding nosology, clinical, biological and imaging features and the unmet need in this field. The last part is dedicating to the present and future of acute treatment in NMSOD and MOGAD.
在这篇迷你综述中，我们重点关注视神经脊髓炎谱系疾病（NMOSD）和髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）领域的新进展。我们首先描述了 MOGAD 的拟议标准，并评估了它们的影响和潜在局限性，重点介绍了仅在脑脊液中检测到 MOG 抗体阳性的患者亚组。然后，我们简要介绍了目前关于所谓的“双血清阴性”NMOSD 组的最新知识，包括分类学、临床、生物学和影像学特征，以及该领域的未满足需求。最后一部分致力于 NMOSD 和 MOGAD 的急性治疗的现状和未来。
